Catalyst Dossier · compiled by CeliA 🧫

Aveo Pharmaceuticals, Inc. (AVEO)

Healthcare · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-01 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-11-01 (est.)Phase 2 · Tivozanibimp 7/10
2027-08-15 (est.)Phase 3 · Ficlatuzumabimp 9/10

Pipeline

Asset	Phase	Indication
tivozanib (AV-951)	Phase 3	Advanced Renal Cell Carcinoma
Sorafenib	Phase 3	Advanced Renal Cell Carcinoma
Ficlatuzumab	Phase 3	Metastatic Head-and-neck Squamous-cell Carcinoma
Tivozanib	Phase 3	Renal Cell Carcinoma
AV-299 + gefitinib	Phase 2	Carcinoma, Non-Small Cell-Lung
Tivozanib hydrochloride	Phase 3	Carcinoma, Renal Cell
mFOLFOX6	Phase 2	Colorectal Cancer
Everolimus	Phase 2	Gastrointestinal Cancer
Tivozanib (1mg)	Phase 2	Advanced Adult Hepatocellular Carcinoma

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for AVEO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.